Sarcomatrix Therapeutics, a clinical-stage biotechnology company focused on revolutionizing treatments for muscle-related diseases, today announced its participation at the 2025 BIO CEO & Investor Conference. The event, set for February 10-11, 2025, at the New York Marriott Marquis, will serve as a platform for Sarcomatrix to showcase its latest advancements in the development of its lead drug candidate, S-969. [Read More: BIO CEO & Investor Conference]
David Craig, CEO of Sarcomatrix, will deliver a presentation detailing the company’s significant progress in preclinical development and its strategic roadmap toward initiating Phase 1 clinical trials in 2025.
What is DMD Drug Candidate S-969?
S-969, a first-in-class small molecule targeting a key kinase on the Hippo-YAP axis, has demonstrated promising potential in addressing debilitating conditions such as Duchenne muscular dystrophy (DMD), sarcopenia, and other degenerative muscle disorders.
“This is a transformative moment for Sarcomatrix as we prepare to transition S-969 into clinical development,” said David Craig. “Our robust preclinical data, coupled with a clear regulatory strategy and growing investor confidence, positions 2025 as a landmark year for our company and the patients we aim to serve.”
Learn More: Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
